Royal Bk Can SEC Filings

Medicus Pharma Ltd. (Nasdaq: MDCX) has filed Prospectus Supplement No. 5 to update its May 29, 2025 prospectus in connection with a definitive securities-exchange agreement signed on June 29, 2025. The company will acquire 100% of Antev Ltd., a clinical-stage biotech developing Teverelix, a next-generation GnRH antagonist targeting cardiovascular high-risk prostate-cancer patients and acute urinary-retention episodes.

Key agreed terms:

• Equity consideration: 2,666,600 Medicus common shares, equal to roughly 17 % of post-transaction shares outstanding ("Consideration Shares").
• Lock-up & voting: Consideration Shares subject to staggered resale restrictions and a 36-month voting agreement in favor of current Medicus management.
• Earn-outs: Antev holders may receive up to US$65 million in contingent payments tied to FDA Phase 2 and NDA milestones for Teverelix.
• Closing timetable: Expected before the end of August 2025, pending Antev shareholder approval and customary regulatory/third-party consents. No assurance of completion is given.

The supplement also reminds investors that Medicus’ 2.26 million common shares are reserved for warrant exercises (strike $4.64, exp. Nov 15 2029). As of June 27 2025, Medicus shares traded at $2.90 and the public warrants at $0.95.

The company reiterates its emerging-growth-company status and directs investors to existing risk-factor disclosures. Forward-looking statements highlight uncertainties around deal consummation, clinical development, regulatory approval, and market opportunity for Teverelix.

Royal Bank of Canada (RBC) has filed a Free Writing Prospectus for Market-Linked One Look Notes with Enhanced Buffer tied to the common stock of Tesla, Inc. (TSLA). Each $10 unit matures in roughly 14 months and offers a fixed Step Up Payment of $3.00–$3.60 (30%-36% return) provided TSLA’s ending value is at least 85% of its starting value. If TSLA declines by more than 15%, investors incur 1-for-1 downside exposure; the maximum loss is 85% of principal. The structure therefore protects the first 15% decline but caps upside at the Step Up Payment.

The notes will not be listed on an exchange, and RBC does not expect a secondary market. Investors face RBC credit risk; changes in the bank’s perceived creditworthiness or hedging activities may affect note value. The public offering price will exceed RBC’s initial estimated value, creating an inherent premium. Tax treatment remains uncertain.

Key terms are finalized on the pricing date. Investors should consult the linked preliminary offering documents for full disclosure, risk factors, and U.S. federal tax considerations.

Bank of Montreal (BMO) is marketing Senior Medium-Term Notes, Series K — Callable Barrier Notes with Contingent Coupons due 31 July 2028. The $1,000-denominated notes are linked to the least-performing of the S&P 500, NASDAQ-100 and Russell 2000 indices.

The notes pay a monthly contingent coupon of 0.625 % (≈7.50 % p.a.) when the closing level of each index on an observation date is at least 70 % of its initial level (the Coupon Barrier). If any index closes below that barrier, no coupon is paid for that month.

Starting 27 January 2026, BMO may call the notes in whole on any observation date, returning par plus any due coupon. If the notes remain outstanding to maturity, the principal repayment depends on index performance. Should the final level of any index be below 70 % of its initial level (a “Trigger Event”), investors lose 1 % of principal for every 1 % decline in the worst-performing index; repayment could be zero. If no Trigger Event occurs, holders receive full principal plus any final coupon.

Key economic terms include: estimated initial value of $955.10 per $1,000 (4.5 % below issue price), CUSIP 06376ENN8, unlisted status, and exposure to BMO’s senior unsecured credit risk. The securities are not FDIC or CDIC insured.

• Pricing Date: 28 Jul 2025 | Settlement: 31 Jul 2025
• Observation Dates: monthly, three trading days before each payment date
• Valuation Date: 26 Jul 2028 | Maturity: 31 Jul 2028
• Coupon Barrier & Trigger Level: 70 % of initial index levels

Royal Bank of Canada (RY) has filed a preliminary 424B2 pricing supplement for a new structured product: Capped Leveraged Buffered MSCI EAFE® Index-Linked Notes. The notes are senior unsecured obligations of RY and mature in roughly 16-18 months. Key investment terms include:

• Upside Participation: 250% of any positive MSCI EAFE® return, capped at a Maximum Settlement Amount of $1,113.50–$1,133.50 per $1,000 note (cap level ~104.54%–105.34% of the initial index level).
• Downside Protection: 12.5% buffer; principal is protected unless the index falls more than 12.5%. Below the buffer, loss accelerates at a buffer rate of ~114.29%, potentially up to full principal loss.
• No Coupons & No Early Redemption: The notes pay no periodic interest and cannot be redeemed prior to maturity.
• Credit Exposure: Repayment depends entirely on RY’s credit; the notes are not FDIC or CDIC insured and are not bail-inable.
• Indicative Pricing: Initial estimated value between $960.30–$990.30 (96.0–99.0% of par), below the $1,000 issue price, implying an initial value discount of up to 3.97%.
• Liquidity: The notes will not be listed on any exchange; secondary market, if any, will be limited and may be at prices below issue price.

Investors seeking enhanced upside to developed-market equities with moderate downside protection may find the structure attractive; however, the payoff is capped, the buffer is limited, and credit/market liquidity risks are material.

Shanghai Fosun Pharmaceutical ("Fosun Pharma") and its U.S. affiliate Fosun Pharma USA Inc. (FPUSA) have sharply reduced their position in Nature's Sunshine Products Inc. (NASDAQ: NATR). On 25 June 2025 FPUSA entered into an underwriting agreement with D.A. Davidson & Co. to sell 2,854,607 common shares at a public offering price of $12.00 per share. After the $0.54 per-share underwriting discount, FPUSA netted $11.46 per share, or roughly $32.7 million. The secondary offering closed on 27 June 2025 and was effected under NATR's Form S-3 shelf registration that became effective on 18 June 2025.

As a result of the sale, Fosun Pharma now beneficially owns 64,167 shares—only 0.35 % of the 18,463,179 shares outstanding—meaning the reporting persons no longer hold more than 5 % of the company's equity. FPUSA has signed a 90-day lock-up restricting further dispositions. Concurrently, NATR may repurchase up to $15.0 million of the offered shares from the underwriter under its existing buy-back programme, potentially offsetting some secondary-market supply.

This Amendment No. 3 to Schedule 13D updates ownership data, adds the underwriting, lock-up and share-repurchase agreements as exhibits, and confirms that the 2.85 million-share sale was the only NATR transaction by the reporting persons since the prior amendment.

Nelnet, Inc. (NNI) Form 4 filing dated 18-Jun-2025 discloses a routine equity award to Director Kimberly Kay Rath. On 16-Jun-2025 she received 1,779 phantom stock units under the company’s Directors Stock Compensation Plan at a reference price of $95.58 per unit. Each unit is convertible 1-for-1 into Class A common shares and will be settled after her board service ends, either in a lump sum or up to five annual installments, at her election.

Following the grant Ms. Rath beneficially owns 63,058 phantom stock units. This total includes 610 additional units accumulated since 18-Jun-2024 through the plan’s dividend-reinvestment feature. The filing reports no open-market purchases or sales of Nelnet common stock, and the ownership remains direct, with no indication of indirect or 10b5-1 trading plans.

The transaction is a standard director compensation event and does not materially alter the company’s share count or insider ownership structure. Investors typically view such awards as neutral to mildly positive because they maintain director equity alignment, but the impact on valuation or near-term trading dynamics is minimal.

Royal Bank of Canada (RY) has filed a Free Writing Prospectus for an issuance of Market-Linked Securities—Auto-Callable with Contingent Coupon and Contingent Downside Principal at Risk maturing on 21 July 2028. The $1,000-denominated notes are linked to the worst performer among Goldman Sachs (GS), Meta Platforms (META) and Exxon Mobil (XOM).

Key structural terms: investors may receive a quarterly contingent coupon of at least 21% p.a. when the lowest-performing stock closes at or above 70% of its starting value. From January 2026 through April 2028 the notes are auto-callable at par plus the current coupon if the worst performer is at or above its starting value on any calculation day. If not called, principal is protected only down to the 70% downside threshold; below that level, repayment is reduced one-for-one with the worst performer’s decline, exposing investors to a potential 100% loss of capital.

Pricing considerations: the issuer’s estimated initial value is $910-$960 (9-4% discount to issue price), reflecting agent fees of up to 2.325% and dealer concessions. Secondary market liquidity is expected to be limited and pricing will be sensitive to equity volatility, dividends, credit spreads and correlation among the three underlyings.

Principal risks include full downside exposure beyond the 30% buffer, possibility of no coupons, reinvestment risk if early called, RBC credit risk, complex tax treatment and potential conflicts of interest with the calculation agent (RBCCM). The product does not participate in any upside of the underlying stocks.

These notes may appeal to investors seeking elevated income and willing to assume equity, issuer-credit and structural risks in exchange for high contingent coupons and a conditional 30% buffer.

Bank of Montreal (BMO) is offering Market Linked Securities—Auto-Callable with Leveraged Upside Participation and Contingent Downside Principal at Risk Securities—linked to the performance of the iShares 20+ Year Treasury Bond ETF (the “Underlier”). Each security has a $1,000 face amount and will price on June 26 2025, with an expected issue date of July 1 2025 and maturity on June 29 2028.

Automatic call feature: If on the single call date (July 1 2026) the Underlier’s closing value is at or above its starting value, the note is automatically called and investors receive the face amount plus a call premium of at least 14.60 %. No further upside is available once called.

Payment at maturity (if not called):

• If the ending value > starting value: $1,000 + ($1,000 × Underlier return × 125 % upside participation).
• If the ending value ≤ starting value but ≥ 75 % of starting value (the “threshold”): return of principal.
• If the ending value < threshold: $1,000 + ($1,000 × Underlier return), resulting in losses greater than 25 % and up to 100 % of principal.

Key structural details: The securities pay no periodic interest, expose holders to BMO credit risk, and will not be listed on any exchange. BMO Capital Markets Corp. is calculation agent. Estimated initial value is $956.90, not less than $920 at pricing, reflecting up to a 2.575 % agent discount to Wells Fargo Securities (of which up to 2.00 % may be a selling concession).

Principal risks highlighted include potential loss of principal below the 75 % threshold, limited upside if automatically called, lack of secondary market liquidity, reinvestment risk, and uncertain U.S. tax treatment. The note provides price-only exposure to the Underlier, excluding its interest distributions.

On 18 June 2025, Omnicell, Inc. (OMCL) filed a Form S-8 to register 1,750,000 additional common shares for issuance under the company’s 2009 Equity Incentive Plan (as amended). The submission references ten earlier S-8 filings dating back to 2009 and incorporates by reference the company’s latest Form 10-K, Form 10-Q and several Form 8-Ks. Customary exhibits—legal opinion, auditor consent, filing-fee table and power of attorney—are included.

This is an administrative capital-markets filing; no new operating or financial data are provided. The registration expands the share reserve available for future equity awards to employees, officers and directors, supporting Omnicell’s long-term compensation strategy. While the move does not immediately change the share count, the issuance and eventual vesting of these awards may create modest dilution for existing shareholders.

• Shares registered: 1,750,000
• Plan affected: Omnicell, Inc. 2009 Equity Incentive Plan
• Principal executive offices: 4220 North Freeway, Fort Worth, TX 76137
• Legal counsel: Foley & Lardner LLP